4 Healthcare Stock Stories for Investor Wellbeing
Johnson & Johnson (NYSE:JNJ): Closing price $72.35
On Thursday, an FDA advisory panel okayed J&J’s canagliflozin, a drug for diabetes that could be the first in a new class of domestic drugs to treat the disease, although several panel members were worried about potential cardiovascular risks and its use in people whose kidneys are impaired. The panel voted 10 to 5, for approval. The drug is part of a new group of drugs that reduces blood sugar by causing blood sugar to be excreted through the urine. Many current treatments work by affecting the supply or use of insulin.